CR20140077A - PROTEINS AND MODIFIED PEPTIDES - Google Patents

PROTEINS AND MODIFIED PEPTIDES

Info

Publication number
CR20140077A
CR20140077A CR20140077A CR20140077A CR20140077A CR 20140077 A CR20140077 A CR 20140077A CR 20140077 A CR20140077 A CR 20140077A CR 20140077 A CR20140077 A CR 20140077A CR 20140077 A CR20140077 A CR 20140077A
Authority
CR
Costa Rica
Prior art keywords
proteins
modified peptides
modified
peptides
terminus
Prior art date
Application number
CR20140077A
Other languages
Spanish (es)
Inventor
Claire Ashman
Mary Birchler
Wildt Rudolf M T De
Claire Holland
Alan Peter Lewis
Peter Morley
Thomas Sandal
Michael Steward
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1121226.3A external-priority patent/GB201121226D0/en
Priority claimed from GBGB1121233.9A external-priority patent/GB201121233D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of CR20140077A publication Critical patent/CR20140077A/en

Links

Landscapes

  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La presente invención se refiere a proteínas y péptidosmodificados que tienen una capacidad reducida para unirse aanticuerpos preexistentes. Dichas moléculas de 5 proteína/péptidomodificadas pueden comprender adiciones, extensiones o etiquetas y/o determinadas sustituciones de aminoácidos en el extremo C terminal.The present invention relates to modified proteins and peptides that have a reduced ability to bind to preexisting antibodies. Said protein / peptide-modified molecules may comprise additions, extensions or labels and / or certain amino acid substitutions at the C-terminus.

CR20140077A 2011-08-17 2014-02-17 PROTEINS AND MODIFIED PEPTIDES CR20140077A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161524488P 2011-08-17 2011-08-17
GBGB1121226.3A GB201121226D0 (en) 2011-12-12 2011-12-12 Modified proteins and peptides
GBGB1121233.9A GB201121233D0 (en) 2011-12-12 2011-12-12 Modified proteins and peptides

Publications (1)

Publication Number Publication Date
CR20140077A true CR20140077A (en) 2014-03-20

Family

ID=50431536

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20140077A CR20140077A (en) 2011-08-17 2014-02-17 PROTEINS AND MODIFIED PEPTIDES

Country Status (2)

Country Link
CL (1) CL2014000381A1 (en)
CR (1) CR20140077A (en)

Also Published As

Publication number Publication date
CL2014000381A1 (en) 2014-07-11

Similar Documents

Publication Publication Date Title
CY1122691T1 (en) SERUM ALBUMIN-BINDING PROTEINS
UA118167C2 (en) Peptides and their use
MX2011011132A (en) Cancer antigen helper peptide.
CL2013003090A1 (en) Polypeptide comprising a first amino acid sequence which in turn comprises at least one individual variable immunoglobulin domain that specifically binds to il-17f, il17-a / f, but not to il-17a, and a second amino acid sequence that it comprises at least one individual variable domain of immunoglobulin that specifically binds to il-17a, il-17f and il17-a / f; pharmaceutical composition that includes it; And its use.
MX2014005108A (en) POLYPEPTIDE CONSTRUCTS AND THEIR USES.
CR11282A (en) PROTEINS LINKED TO THE HUMAN FELINO MCDONOUGH CEPA CELL ANTIGEN
CO6630173A2 (en) Seroalbuminae binding molecules
ES2684475T3 (en) Proteins that bind to beta amyloid
CY1123304T1 (en) INHIBITING PEPTIDES DERIVED FROM TREM TRANSCRIPTION TYPE 1 (TLT-1) AND USES THEREOF
MX337873B (en) Antibody drug conjugates (adc) that bind to 191p4d12 proteins.
EA201400568A1 (en) ALBUMINS CONNECTING ANTIBODIES AND THEIR CONNECTING FRAGMENTS
CL2013001124A1 (en) Isolated antibody or a protein comprising an antigen binding portion of an antibody directed against a cd40 polypeptide; pharmaceutical composition comprising said antibody; nucleic acid encoding the antibody; cloning vector; antibody production process.
DK2831241T3 (en) ARTIFICIAL NUCLEIC ACID MOLECULES FOR IMPROVED PROTEIN OR PEPTIDE EXPRESSION.
MX374682B (en) 4-1BB BINDING MOLECULES.
CY1116842T1 (en) SPECIFICALLY HUMANIZED ANTIBODIES IN THE PROTEINOLOGICAL FORM OF BETA-AMYLOID Peptide
CA2872308A1 (en) Novel ha binding agents
CL2013002888A1 (en) Antibody that binds antigenic peptide that is obtained from a tau protein; pharmaceutical composition comprising; use to treat neurodegenerative disorder or disease; test kit, cell line (div 2457-2011).
EA201792245A1 (en) BIOCONJUGATES AND THEIR APPLICATIONS
EA201491049A1 (en) ANTI-TRACT FUSE PROTEIN
PE20120170A1 (en) IMPROVED ANTI-ALBUMIN BINDING VARIANTS
EA201291065A1 (en) ANTIBODIES AGAINST VLA-4
UA115436C2 (en) Anticancer fusion protein
PL393578A1 (en) Anticancer fusion protein
CR11059A (en) NEW NUCLEIC ANTIBODY MOLECULES AND NUCLEIC ACIDS THAT LINK WITH THE FUNGICAL TENSION PROTEIN HSP90
BR112014028130A2 (en) HYDROchloride salt of a peptide, pharmaceutical composition, use of a hydrochloride salt, use of a pharmaceutical composition, and method of preventing or treating cat allergy